CrossTalk opposing view: The late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction)

Journal of Physiology

Volumn 592, Issue 3, 2014, Pages 415-417

  Papp, Zoltán ^a   Borbély, Attila ^a   Paulus, Walter J ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; RANOLAZINE; SODIUM ION;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; DIASTOLIC HEART FAILURE; DRUG SPECIFICITY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SODIUM CURRENT;

ANIMALS; CALCIUM; DIASTOLE; HEART FAILURE; HUMANS; SODIUM; SODIUM CHANNELS;

EID: 84893416796     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.264242     Document Type: Article

References (29)

1. Anderson ME, Brown JH & Bers DM (2011). CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51, 468-473.
2. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM & Thomas G (2004). Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910.
3. Bers DM (2000). Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 87, 275-281.
4. + regulation in cardiac myocytes. Cardiovasc Res 57, 897-912.
5. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ & Paulus WJ (2005). Cardiomyocyte stiffness in diastolic heart failure. Circulation 111, 774-781.
6. De Keulenaer GW & Brutsaert DL (2011). Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 123, 1996-2004.
7. Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Dungen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuss G, Pieske BM & Wachter R (2011). Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100, 755-764.
8. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ & Clanachan AS (2006). Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 41, 1031-1038.
9. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99, 641-648.
10. Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC & Kloner RA (2009). Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation 120, S16-S21.
11. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ & Dudley SC Jr. (2012). Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 110, 841-850.
12. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G & Jacobshagen G (2013). RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF proof-of-concept study. J Am Coll Cardiol HF 1, 115-122.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14, 803-869.
14. Maltsev VA, Sabbah HN, Higgins RS, Silverman N, Lesch M & Undrovinas AI (1998). Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 98, 2545-2552.
15. Maltsev VA & Undrovinas A (2008). Late sodium current in failing heart: friend or foe? Prog Biophys Mol Biol 96, 421-451.
16. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S & Robinson JL (2008). Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19, 1289-1293.
17. Paulus WJ & Tschope C (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62, 263-271.
18. i handling in the failing human heart. Cardiovasc Res 57, 874-886.
19. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC & Sabbah HN (2008). Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 295, H2149-H2155.
20. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A & Stanley WC (2002). Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 8, 416-422.
21. Schouten VJ & ter Keurs HE (1986). The force-frequency relationship in rat myocardium. The influence of muscle dimensions. Pflugers Arch 407, 14-17.
22. Shah AM & Solomon SD (2012). Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction. Eur Heart J 33, 1716-1717.
23. 2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res 107, 1150-1161.
24. + current. Basic Res Cardiol 106, 263-272.
25. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L & Maier LS (2008). Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 45, 32-43.
26. 2+ accumulation in chronic heart failure. J Physiol Sci 60, 245-257.
27. van Heerebeek L, Franssen CP, Hamdani N, Verheugt FW, Somsen GA & Paulus WJ (2012). Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 9, 293-302.
28. + channels. J Clin Invest 116, 3127-3138.
29. Zhang XQ, Yamada S & Barry WH (2008). Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia. J Cardiovasc Pharmacol 51, 443-449.